AssetMark Inc
IOVA icon

AssetMark Inc’s Iovance Biotherapeutics IOVA Stock Holding History

AssetMark Inc’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$761 Hold
183
– – ﹤0.01% 3203
2026
Q1 		$642 Hold
183
– – ﹤0.01% 3132
2025
Q4 		$500 Sell
183
-11,026
-98% -$25.5K ﹤0.01% 3102
2025
Q3 		$24.3K Sell
11,209
-2,705
-19% -$6.39K ﹤0.01% 1862
2025
Q2 		$23.9K Sell
13,914
-542
-4% -$1.35K ﹤0.01% 1764
2025
Q1 		$48.1K Buy
14,456
+2,397
+20% +$12.4K ﹤0.01% 1449
2024
Q4 		$89.2K Sell
12,059
-794
-6% -$7.36K ﹤0.01% 1277
2024
Q3 		$121K Buy
12,853
+4,167
+48% +$39.5K ﹤0.01% 1117
2024
Q2 		$69.7K Buy
8,686
+2,736
+46% +$29.3K ﹤0.01% 1171
2024
Q1 		$88.2K Sell
5,950
-3,580
-38% -$41.7K ﹤0.01% 1065
2023
Q4 		$77.5K Buy
9,530
+654
+7% +$3.42K ﹤0.01% 1076
2023
Q3 		$40.4K Buy
8,876
+2,718
+44% +$17.7K ﹤0.01% 1140
2023
Q2 		$43.4K Buy
6,158
+1,935
+46% +$13.8K ﹤0.01% 1114
2023
Q1 		$25.8K Buy
4,223
+3,166
+300% +$21.8K ﹤0.01% 1157
2022
Q4 		$6.75K Buy
1,057
+233
+28% +$1.82K ﹤0.01% 1327
2022
Q3 		$8K Buy
824
+329
+66% +$3.79K ﹤0.01% 1247
2022
Q2 		$5K Buy
495
+231
+88% +$3.03K ﹤0.01% 1303
2022
Q1 		$4K Buy
+264
New +$4.08K ﹤0.01% 1316

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

AssetMark Inc's IOVA Position: Q2 2026 in Review

AssetMark Inc held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 183 shares worth $761. The position accounts for ﹤0.01% of the portfolio, ranked #3203.

AssetMark Inc first reported a position in IOVA in Q1 2022 and has held it in 18 quarters since. The position peaked at $121K in Q3 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • AssetMark Inc held 183 shares of Iovance Biotherapeutics worth $761 as of Q2 2026.
  • AssetMark Inc left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3203 holding.
  • AssetMark Inc first reported a position in Iovance Biotherapeutics in Q1 2022 and has held it in 18 quarters since.
  • AssetMark Inc's Iovance Biotherapeutics position peaked at $121K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.